Waters Corporation is a global leader in analytical laboratory instrumentation and software, specializing in the development and manufacture of advanced technologies for liquid chromatography, mass spectrometry, and thermal analysis. The company serves a diverse range of industries, including pharmaceuticals, biotechnology, food and beverage, environmental, and academic research, providing essential tools for scientific research, quality control, and regulatory compliance. With a strong emphasis on innovation and precision, Waters is dedicated to helping scientists and researchers optimize their analytical processes and obtain reliable, high-quality data to further their work. Read More
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
Scientific instruments company Waters Corporation (NYSE:WAT) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 3.9% year on year to $661.7 million. Guidance for next quarter’s revenue was better than expected at $751 million at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $2.25 per share was 1.3% above analysts’ consensus estimates.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Agilent (NYSE:A) and its peers.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the research tools & consumables industry, including Waters Corporation (NYSE:WAT) and its peers.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
While the broader market has struggled with the S&P 500 down 1.7% since September 2024, Waters Corporation has surged ahead as its stock price has climbed by 13.1% to $382.94 per share. This run-up might have investors contemplating their next move.
Looking back on research tools & consumables stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Sotera Health Company (NASDAQ:SHC) and its peers.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Danaher (NYSE:DHR) and the best and worst performers in the research tools & consumables industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst performers in the research tools & consumables industry.
Shares of scientific instruments company Waters Corporation (NYSE:WAT)
fell 9% in the morning session after the company reported disappointing fourth quarter results: Its revenue and EPS guidance for next quarter fell short of Wall Street's estimates. whole, was underwhelming. The company highlighted headwinds related to foreign exchange, volume, and inflation. Also, the sales outlook suggests growth will trudge along in the mid-single digits, given foreign exchange pressures.
